Most of these little biotechs just do “free” research for BP. So occasionally BP helps them raise cash from retail so their own R&D isn’t so high just to make their shareholders happy. You see how it works?
It’s not unreasonable that covid brought on a case of cold feet in leaving a secure behemoth for a cash strapped biopharma. Or, that the snail’s pace of missed deadlines and empty promises didn’t sit well with him. Or, just maybe, he got sick of Les trying to show him Andrew Dice Clay videos on his phone every time he tried to get a cup of coffee in the break room.
News 
Market Data 
Discover 
AI
